Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month High – Should You Buy?

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $51.36 and last traded at $51.06, with a volume of 1289453 shares trading hands. The stock had previously closed at $45.06.

Analysts Set New Price Targets

MAZE has been the topic of several analyst reports. Mizuho assumed coverage on Maze Therapeutics in a report on Tuesday. They set an “outperform” rating and a $97.00 target price on the stock. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $54.63.

Maze Therapeutics Trading Up 13.3%

The stock has a 50-day moving average price of $44.22 and a 200 day moving average price of $35.12. The stock has a market capitalization of $2.46 billion, a price-to-earnings ratio of -2.44 and a beta of 4.47.

Insiders Place Their Bets

In other Maze Therapeutics news, SVP Amy Bachrodt sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the sale, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $526,119.70. This trade represents a 43.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Harold Bernstein sold 45,000 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 200,000 shares of company stock worth $8,254,792.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its position in Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after acquiring an additional 2,390,713 shares during the period. Vanguard Group Inc. grew its position in shares of Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after purchasing an additional 915,342 shares during the period. Marshall Wace LLP increased its stake in shares of Maze Therapeutics by 3,868.5% during the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after purchasing an additional 758,104 shares in the last quarter. Caligan Partners LP purchased a new stake in shares of Maze Therapeutics during the fourth quarter worth about $22,794,000. Finally, ArrowMark Colorado Holdings LLC acquired a new position in shares of Maze Therapeutics during the 3rd quarter worth about $14,135,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.